Biocryst is an English word starting with the letter B. With 10+ example sentences you'll see exactly how it works in context.
Biocryst in a sentence
Using Biocryst
- In the example corpus, biocryst often appears in combinations such as: biocryst pharmaceuticals, in biocryst, of biocryst.
Context around Biocryst
- Average sentence length in these examples: 22.1 words
- Position in the sentence: 5 start, 9 middle, 0 end
- Sentence types: 14 statements, 0 questions, 0 exclamations
Corpus analysis for Biocryst
- In this selection, "biocryst" usually appears in the middle of the sentence. The average example has 22.1 words, and this corpus slice is mostly made up of statements.
- Around the word, cut, upgraded and pharmaceuticals stand out and add context to how "biocryst" is used.
- Recognizable usage signals include shares of biocryst pharmaceuticals in and stake in biocryst pharmaceuticals in. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "biocryst" sits close to words such as aat, abhorrence and abms, which helps place it inside the broader word index.
Example types with biocryst
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
BioCryst Pharmaceuticals () last issued its quarterly earnings results on Tuesday, February 21st. (12 words)
Piper Jaffray Companies initiated coverage on BioCryst Pharmaceuticals in a report on Friday, November 16th. (15 words)
Kynam Capital Management LP grew its stake in BioCryst Pharmaceuticals by 41.9% during the first quarter. (17 words)
Jefferies Financial Group raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Friday, August 4th. (34 words)
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat. (33 words)
Zacks Investment Research upgraded BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.75 target price for the company in a research report on Tuesday, October 9th. (33 words)
Example sentences (14)
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.
BioCryst Pharmaceuticals () last issued its quarterly earnings results on Tuesday, February 21st.
Fairfield Bush & CO. bought a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter worth about $34,000.
Jefferies Financial Group raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a research note on Friday, August 4th.
HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th.
Kynam Capital Management LP grew its stake in BioCryst Pharmaceuticals by 41.9% during the first quarter.
Needham & Company LLC reiterated a “buy” rating and set a $12.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, January 8th.
NewSquare Capital LLC acquired a new position in BioCryst Pharmaceuticals in the 4th quarter valued at $26,000.
Amalgamated Bank purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter worth approximately $122,000.
Bank of America Corp DE increased its position in BioCryst Pharmaceuticals by 32.5% during the fourth quarter.
BidaskClub cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 31st.
Dynamic Technology Lab Private Ltd purchased a new stake in BioCryst Pharmaceuticals in the third quarter worth $122,000.
Piper Jaffray Companies initiated coverage on BioCryst Pharmaceuticals in a report on Friday, November 16th.
Zacks Investment Research upgraded BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.75 target price for the company in a research report on Tuesday, October 9th.
Common combinations with biocryst
These word pairs occur most frequently in English texts:
- biocryst pharmaceuticals 15×
- in biocryst 5×
- of biocryst 4×
- for biocryst 2×